210 related articles for article (PubMed ID: 23318765)
1. Arsenic speciation in saliva of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Chen B; Cao F; Yuan C; Lu X; Shen S; Zhou J; Le XC
Anal Bioanal Chem; 2013 Feb; 405(6):1903-11. PubMed ID: 23318765
[TBL] [Abstract][Full Text] [Related]
2. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Wang Z; Zhou J; Lu X; Gong Z; Le XC
Chem Res Toxicol; 2004 Jan; 17(1):95-103. PubMed ID: 14727923
[TBL] [Abstract][Full Text] [Related]
3. Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient.
Iriyama N; Yoshino Y; Yuan B; Horikoshi A; Hirabayashi Y; Hatta Y; Toyoda H; Takeuchi J
J Hematol Oncol; 2012 Jan; 5():1. PubMed ID: 22272800
[TBL] [Abstract][Full Text] [Related]
4. Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia.
Yoshino Y; Yuan B; Miyashita SI; Iriyama N; Horikoshi A; Shikino O; Toyoda H; Kaise T
Anal Bioanal Chem; 2009 Jan; 393(2):689-97. PubMed ID: 19009285
[TBL] [Abstract][Full Text] [Related]
5. Monomethylated arsenic was the Major methylated arsenic in Red blood cells of acute promyelocytic leukemia patients treated with arsenic trioxide.
Guo S; Wang X; Gao C; Wu Z; Chen H; Lin L; Guo M; Gao Y; Hai X
Toxicol Lett; 2021 Sep; 347():78-85. PubMed ID: 33865921
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: speciation of arsenic metabolites in serum and urine.
Fukai Y; Hirata M; Ueno M; Ichikawa N; Kobayashi H; Saitoh H; Sakurai T; Kinoshita K; Kaise T; Ohta S
Biol Pharm Bull; 2006 May; 29(5):1022-7. PubMed ID: 16651738
[TBL] [Abstract][Full Text] [Related]
7. Arsenic speciation in hair and nails of acute promyelocytic leukemia (APL) patients undergoing arsenic trioxide treatment.
Chen B; Cao F; Lu X; Shen S; Zhou J; Le XC
Talanta; 2018 Jul; 184():446-451. PubMed ID: 29674067
[TBL] [Abstract][Full Text] [Related]
8. Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide.
Guo M; Wang B; Liu S; Wang W; Gao C; Hu S; Fan S; Hai X; Zhou J
Expert Rev Clin Pharmacol; 2019 Apr; 12(4):371-378. PubMed ID: 30795697
[TBL] [Abstract][Full Text] [Related]
9. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
[TBL] [Abstract][Full Text] [Related]
10. Determination of arsenic metabolites in patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide.
Zhang Z; Chen Y; Meng H; Sui M; Zhou Q; Shi C; Han L; Wang H; Zhou J
Leuk Lymphoma; 2013 Sep; 54(9):2041-6. PubMed ID: 23343178
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of arsenic trioxide in acute promyelocytic leukemia cells.
Khaleghian A; Ghaffari SH; Ahmadian S; Alimoghaddam K; Ghavamzadeh A
J Cell Biochem; 2014 Oct; 115(10):1729-39. PubMed ID: 24819152
[TBL] [Abstract][Full Text] [Related]
12. Arsenic speciation analysis in human saliva.
Yuan C; Lu X; Oro N; Wang Z; Xia Y; Wade TJ; Mumford J; Le XC
Clin Chem; 2008 Jan; 54(1):163-71. PubMed ID: 17981925
[TBL] [Abstract][Full Text] [Related]
13. Speciation analysis of arsenic in urine samples from APL patients treated with single agent As
Guo M; Li J; Fan S; Liu W; Wang B; Gao C; Zhou J; Hai X
J Pharm Biomed Anal; 2019 Jul; 171():212-217. PubMed ID: 31009876
[TBL] [Abstract][Full Text] [Related]
14. Monomethylarsonous acid binds to Cys-104α and Cys-112β of hemoglobin in acute promyelocytic leukemia patients treated with arsenic trioxide.
Gao C; Lin L; Li J; Wu M; Lv J; Tian S; Hai X
Toxicol Lett; 2023 May; 380():31-39. PubMed ID: 37024065
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic Properties of Arsenic Species after Intravenous and Intragastrical Administration of Arsenic Trioxide Solution in Cynomolgus Macaques Using HPLC-ICP-MS.
Shi Q; Ju M; Zhu X; Gan H; Gu R; Wu Z; Meng Z; Dou G
Molecules; 2019 Jan; 24(2):. PubMed ID: 30634677
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of arsenic species in leukocytes and granulocytes of acute promyelocytic leukemia patients treated with arsenic trioxide.
Wang X; Qian Z; Li H; Chen H; Lin L; Guo M; Hai X
J Pharm Biomed Anal; 2021 Sep; 203():114201. PubMed ID: 34130006
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia.
Gao C; Hu S; Guo M; Hai X; Zhou J
Cancer Chemother Pharmacol; 2018 Aug; 82(2):229-236. PubMed ID: 29845392
[TBL] [Abstract][Full Text] [Related]
18. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells.
Chen GQ; Zhou L; Styblo M; Walton F; Jing Y; Weinberg R; Chen Z; Waxman S
Cancer Res; 2003 Apr; 63(8):1853-9. PubMed ID: 12702573
[TBL] [Abstract][Full Text] [Related]
19. Species variations in the biliary and urinary excretion of arsenate, arsenite and their metabolites.
Csanaky I; Gregus Z
Comp Biochem Physiol C Toxicol Pharmacol; 2002 Mar; 131(3):355-65. PubMed ID: 11912060
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide.
Fujisawa S; Ohno R; Shigeno K; Sahara N; Nakamura S; Naito K; Kobayashi M; Shinjo K; Takeshita A; Suzuki Y; Hashimoto H; Kinoshita K; Shimoya M; Kaise T; Ohnishi K
Cancer Chemother Pharmacol; 2007 Mar; 59(4):485-93. PubMed ID: 16937107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]